The Latest Cardiac and Vascular News
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces that Houston-based resTOR Longevity Clinic will integrate Cardio Diagnostics’ solutions into its battery of tests for new patients in its longevity-focused concierge clinic. This collaboration marks a significant milestone for Cardio Diagnostics, as resTOR will be the […]
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor. Dr. Ramjee is a cardiologist and a health innovation leader, serving as the National Co-Chair of Cardiology and Innovation at CommonSpirit Health Enterprise and […]
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics today announced the AMA CPT Editorial Panel is reviewing its Epi+Gen CHD and PrecisionCHD tests for CPT PLA codes.
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics today announced the publication of its groundbreaking study in the Journal of the American Heart Association (JAHA),
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced a significant move to transform global cardiovascular health, by entering into a Supply and Distribution Agreement with one of India’s premier organizations, Aimil Ltd. Aimil, a company at the forefront of the instrumentation industry […]
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced its AI-driven Epi+Gen CHD and PrecisionCHD tests will be leveraged in a research study led by Dr. Vishal Gupta, a cardiologist and the head of the Heart Attack Prevention Clinic at Ascension Borgess. […]
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced that Australia’s Patent Office has issued a Notice of Allowance to the University of Iowa Research Foundation (“UIRF”) for Australian Patent Application No. 2017277666, titled “Compositions and Methods for Detecting Predisposition to Cardiovascular […]
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, announced the publication of groundbreaking research in the journal Genes. The study titled “The Reversion of the Epigenetic Signature of Coronary Heart Disease in Response to Smoking Cessation” sheds light on the potential of […]
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, announced the introduction of the Actionable Clinical IntelligenceTM (ACI) platform to expand the information available to clinicians prescribing the Epi+Gen CHD and PrecisionCHD laboratory developed tests (LDTs). ACI offers new data-driven insights into the epigenetic and genetic molecular […]
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a precision cardiovascular medicine company, today announced a partnership with Connect Clinic to help MidWest/South Central self-insured employers build access to heart disease initiatives. These states lack ready access to precision heart disease technologies needed to tackle cardiovascular disease at scale while also having […]
